Document Detail


Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia.
MedLine Citation:
PMID:  16540702     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
There is good evidence that clozapine is more efficacious than first-generation antipsychotic drugs in resistant schizophrenia. It is less clear if clozapine is more effective than the other second-generation antipsychotic (SGA) drugs. A noncommercially funded, pragmatic, open, multisite, randomized controlled trial was conducted in the United Kingdom National Health Service (NHS). Participants were 136 people aged 18-65 with DSM-IV schizophrenia and related disorders whose medication was being changed because of poor clinical response to 2 or more previous antipsychotic drugs. Participants were randomly allocated to clozapine or to one of the class of other SGA drugs (risperidone, olanzapine, quetiapine, amisulpride) as selected by the managing clinician. Outcomes were assessed blind to treatment allocation. One-year assessments were carried out in 87% of the sample. The intent to treat comparison showed no statistically significant advantage for commencing clozapine in Quality of Life score (3.63 points; CI: 0.46-7.71; p = .08) but did show an advantage in Positive and Negative Syndrome Scale (PANSS) total score that was statistically significant (-4.93 points; CI: -8.82 to -1.05; p = .013) during follow-up. Clozapine showed a trend toward having fewer total extrapyramidal side effects. At 12 weeks participants who were receiving clozapine reported that their mental health was significantly better compared with those receiving other SGA drugs. In conclusion, in people with schizophrenia with poor treatment response to 2 or more antipsychotic drugs, there is an advantage to commencing clozapine rather than other SGA drugs in terms of symptom improvement over 1 year.
Authors:
Shôn W Lewis; Thomas R E Barnes; Linda Davies; Robin M Murray; Graham Dunn; Karen P Hayhurst; Alison Markwick; Helen Lloyd; Peter B Jones
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2006-03-15
Journal Detail:
Title:  Schizophrenia bulletin     Volume:  32     ISSN:  0586-7614     ISO Abbreviation:  Schizophr Bull     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-09-06     Completed Date:  2007-01-29     Revised Date:  2013-06-07    
Medline Journal Info:
Nlm Unique ID:  0236760     Medline TA:  Schizophr Bull     Country:  United States    
Other Details:
Languages:  eng     Pagination:  715-23     Citation Subset:  IM    
Affiliation:
University of Manchester, London. shon.lewis@manchester.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Antipsychotic Agents / adverse effects,  therapeutic use*
Clozapine / adverse effects,  therapeutic use*
Depressive Disorder / diagnosis,  drug therapy,  psychology
Drug Resistance
Female
Follow-Up Studies
Humans
Male
Middle Aged
Psychiatric Status Rating Scales
Quality of Life / psychology
Schizophrenia / diagnosis,  drug therapy*
Schizophrenic Psychology
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 5786-21-0/Clozapine
Comments/Corrections
Comment In:
Evid Based Ment Health. 2007 May;10(2):57   [PMID:  17459988 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The psychotherapist and the sign language interpreter.
Next Document:  Exercise training in normobaric hypoxia in endurance runners. I. Improvement in aerobic performance ...